CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelly, D.
Right arrow Articles by Brull, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, D.
Right arrow Articles by Brull, S. J.

Canadian Journal of Anesthesia, Vol 41, 845-849, Copyright © 1994 by Canadian Anesthesiologists' Society

ARTICLES

Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine?

D Kelly and SJ Brull
Department of Anesthesiology, Yale University School of Medicine, New Haven, CT 06510.

Neuroleptic malignant syndrome (NMS) and malignant hyperthermia (MH) may have a common pathogenic mechanism; therefore, it has been suggested that known triggering agents for MH (such as succinylcholine) should be avoided in patients with NMS. Electroconvulsive therapy (ECT) continues to play a major therapeutic role in contemporary psychiatry, and succinylcholine has been the muscle relaxant of choice in attenuating violent muscle contractions induced by ECT. Mivacurium is a non-depolarizing muscle relaxant with a relatively rapid onset and a short duration of action, and to date it has been proved safe in MH-susceptible patients. In this case report, following succinylcholine use during ECT, a patient with NMS developed an increase in temperature and serum creatine kinase (CK) level, possibly due to an MH reaction. Since the patient's mental status necessitated further ECT, mivacurium was administered during subsequent treatment and resulted in effective attenuation of muscle contractions without elevation of patient temperature or CK levels. In addition, there was no marked prolongation of the anaesthetic. Mivacurium is a suitable agent for patients with NMS undergoing ECT, as it has not been associated with precipitation of an MH response.


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
Z. Ding and P. F. White
Anesthesia for Electroconvulsive Therapy
Anesth. Analg., May 1, 2002; 94(5): 1351 - 1364.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
A. G. Kadar, B. A. Kramer, M. C. Barth, and P. F. White
Rapacuronium: An Alternative To Succinylcholine For Electroconvulsive Therapy
Anesth. Analg., May 1, 2001; 92(5): 1171 - 1172.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the Canadian Anesthesiologists' Society.